Achillion Aiming For Best-In-Class Protease Inhibitor, Working On Home-Grown Hep C Cocktail

While hepatitis C drug developers ponder the safety and tolerability issues likely to arise when direct-acting antivirals are combined in cocktails against the virus, Achillion Pharmaceuticals, Inc., a small company in New Haven, CT, is working on a portfolio of candidates it says not only combine safely, they work better in combination.